The Acceptability of HPV Vaccination Among Women Attending the University of Saskatchewan Student Health Services

Journal of Obstetrics and Gynaecology Canada

Volumn 32, Issue 7, 2010, Pages 679-686

  Giede, Christopher ^a   McFadden, Laura Lee ^a   Komonoski, Pam ^b   Agrawal, Anita ^a   Stauffer, Ardelle ^a   Pierson, Roger ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Acceptability; Barriers; HPV; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; DRUG COST; FEMALE; HEALTH BELIEF; HEALTH LITERACY; HUMAN; PAPILLOMAVIRUS INFECTION; SCHOOL HEALTH SERVICE; STUDENT ATTITUDE; UNIVERSITY STUDENT; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; YOUNG ADULT; ATTITUDE TO HEALTH; CANADA; HEALTH SERVICE; PATIENT ATTITUDE; QUESTIONNAIRE; UNIVERSITY;

ADULT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; SASKATCHEWAN; STUDENT HEALTH SERVICES; UNIVERSITIES;

EID: 77957256407     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34572-8     Document Type: Article

References (46)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 89:12-19.
2. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
3. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention, and role of human papillomavirus infection. CMAJ 2001, 164:1017-1025.
4. Benedet J.L., Bertrand M.A., Natisic J.M., Barner D. Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada. J Low Genit Tract Dis 2005, 9:160-166.
5. Chesson H.W., Blandford J.M., Gift T.L., Tao G., Irwin K.L. The estimated direct medical cost of sexually transmitted disease among American youth, 2000. Prespect Sexual Reprod Health 2004, 36:11-19.
6. Harper D.M., El Franco, Wheeler C., Moscicki A., Romanowski B., Martins Roteli Sustained efficacy up to 4.5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial 2006, 367:1247-1255.
7. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) LI virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
8. Health Policy Monitor. HPV vaccine_funded_in Canada. Available at:. Accessed May 6, 2010. http://www.hpm.org/en/index.html.
9. Society of Obstetricians and Gynaecologists of Canada. HPVinfo.ca. Available at: Accessed May 6, 2010. http://www.hpvinfo.ca/hpvinfo/parents/vaccination-4.aspx.
10. Wright T.C., Huh W.K., Monk B.J., Smith J.S., Ault K., Herzog T.J. Age considerations when vaccinating against HPV. Gynecol Oncol 2008, 109:S40-S47.
11. Brown D.R., Shew M.L., Qadadn B., Neptune N., Vargas M., Tu W., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191:182-192.
12. Burk R.D., Ho G.Y., Beardsley L., Lempa M., Peters M., Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996, 174:679-689.
13. Myers E.R., McCrory D.C., Nanda K., Bastian L., Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151:1158-1171.
14. Munoz N., Bosch F.X., Castellsagué X., Diaz M., De Sanjose, Hammouda D. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-285.
15. Markowitz LE. Quadrivalent HPV vaccine update. ACIP 2007 February 22, 2007. Available at: Accessed January 3, 2008. http://www.cdc.gov/vccmes/recs/acip/slides-feb07.htm.
16. Boehner C.W., Howe S.R., Bernstein D.I., Rosenthal S.L. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 2003, 30:774-778.
17. Lenehan J.G., Leonard K.C., Nandra S., Isaacs C.R., Mathew A., Fisher W.A. Women's knowledge, attitudes, and intentions concerning human-papillomavirus vaccination: findings of a waiting room survey of obstetrics-gynaecology outpatients. J Obstet Gynaecol Can 2008, 29:489-499.
18. Agosti J.M., Goldie S.J. Introducing HPV vaccine in developing countries-key challenges and issues. N Eng J Med 2007, 356:1908-1910.
19. Sauvageau C., Duval B., Gilca V., Lavoie F., Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec. Canada. BMC Public Health 2007, 7:304.
20. Medical News Today. FDA announces approval Of HPV vaccine Gardasil. Available at:. Accessed May 6, 2010. http://www.medicalnewstoday.com/articles/44974.php.
21. Society of Obstetricians and Gynaecologists of Canada. SexualityandU. Available at:. Accessed May 6, 2010. http://www.sexualityandu.ca/home_e.aspx.
22. Provincial Health Services Authority of BC. Immunize BC: diseases and vaccinations-HPV. Available at:. Accessed May 6, 2010. http://www.immunizebc.ca/ImmVacPrevDis/hpv/default.htm.
23. Health Canada. Healthy living: HPV. Available at:. Accessed May 6, 2010. http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/diseases-maladies/hpv-vph-eng.php.
24. Ford C.A., English A., Davenport A.F., Stinnett A.J. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J Adolesc Health Care 2009, 44:568-574.
25. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
26. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficay of a prophylactic adjuvant bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet 2007, 369:2161-2170. HPV PATRICIA study group.
27. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Females United to Unilaterally Reduce Endo/ Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogential diseases. N Engl J Med 2007, 356:1928-1943.
28. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N EnglJ Med 2002, 347:1645-1651.
29. Department of Health and Human Services, Centers of Disease Control and Prevention. Reports of Health Concerns Following HPV vaccination. Available at:. Accessed May 6, 2010. http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm.
30. Ohri L.K. HPV vaccine: immersed in controversy. Ann Pharmacother 2007, 41:1899-1902.
31. Anhang R., Stryker J.E., Wright T.C., Goldie S.J. News Media coverage of human papillomavirus. Cancer 2004, 100:308-314.
32. Manhart L.E., Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002, 29:725-735.
33. Winer R.L., Hughes J.P., Feng Q., Oreilly S., Kiviat N.B., Holmes K.K. Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. N Engl J Med 2006, 354:25:2645-25:2654.
34. Bearman P.S., Moody J., Stovel K. Chains of affection: the structure of adolescent romantic and sexual networks. Am J Sociol 2004, 110:44-91.
35. Winer R.L., Feng Q., Hughes J.P., O'Reilly S., Kiviat N.B., Koutsky L.A. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008, 197:279-282.
36. Bosch F.X., Castellsague X., Munoz N., de Sanjosé S., Ghaffari A.M., Gonzalez L.C., et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996, 88:1060-1067.
37. Agarwal S.S., Sehgal A., Sardana S., Kumar A., Luthra U.K. Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 1993, 72:1666-1669.
38. Charo R.A. Politics, parents, and prophylaxis- mandating HPV vaccination in the United States. N Engl J Med 1905-7, 356:19.
39. Gerend M.A., Lee S.C., Shepherd J.E. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007, 34:468-471.
40. Ault K.A. Effect of prophylactic human papillomavirus LI virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
41. Schwarz T.F., Dubin G. The HPV vaccine study investigators for adult women, human papillomavirus (HPV) 16/18 LI AS04 virus-like particle JVLP) cervical cancer vaccine is immunogenic and well tolerated 18 months after vaccination in women up to age 55 years [abstract]. J Clin Oncol 2007: ASCO Annual Meeting Proceedings Part I 2007, 25(18S):3007. Abstract.
42. Luna J., Saah A., Hood S., Bautista O., Barr E. Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (Gardisil) in women aged 24-25. 24th International Papillomavirus Congress 2007 November 3-9 2007, China, Beijing.
43. Brown R.D., Kjaer S.K., Sigurdsson K., Iversen O., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus ÍHPV; Types 6, 11, 16, and 18) LI virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infec Dis 2009, 199:926-935.
44. Franco E.L., Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 2007, 3:319-327.
45. Jakobsson M., Gissler M., Sainio S., Paavonen J., Tapper A.M. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007, 109:309-313.
46. Wiesberg E., Bateson D., McCaffery K., Skinner S.R. HPV vaccination catch up program: utilization by young Australian women. Aust Fam Physician 2009, 30:72-76.